NexPoint Real Estate Finance

58 per diluted share, as the commercial mortgage REIT expanded its investment portfolio and refinanced a maturing unsecured debt obligation. 54 per diluted share in the year-earlier period. 46 per diluted share. 16 times by cash available for distribution. 50-per-share dividend for the third quarter, payable following its July 27 declaration. Debt Refinancing and Capital Structure Richards highlighted the closing of a $375 million drawable term loan facility with Mizuho Capital Markets as the quarter’s most significant development. 75% senior unsecured notes that matured May 1.

2 million was outstanding under the facility. The company also entered a total return swap with Mizuho that Richards said reduced the impact of its net interest cost to SOFR plus 245 basis points. Richards said the transaction removed the company’s largest near-term liability overhang and replaced fixed-rate unsecured debt with floating-rate, asset-based financing. He said the structure provides greater prepayment flexibility and a leverage solution for new investments. 6 million through its Series C preferred offering. Richards said retained operating cash flow, preferred-offering proceeds and additional secured financing capacity supported new investments during the quarter.

60, primarily because of a small unrealized loss in the company’s stock loan portfolio. 1 billion. 6%. 39 times. 6 years. 88 times. 43. 55. Residential, Life Science and Storage Trends Chief Investment Officer Matt McGraner said the company sees improving residential operating trends. 2% in May and negative 50 basis points in June, before turning positive by 30 basis points in July. McGraner said new leases remained a drag, while renewals held up well. He said multifamily supply had pressured pricing in 2024 and 2025, but cited CoStar forecasts for 2026 deliveries to decline about 49% from 2025 and for 2027 deliveries to fall another 20%.

In life sciences, McGraner said the LYFE property was tracking to reach 85% leased, up from 71%, anchored by a long-term lease with Lila Sciences for 245,000 square feet and expansion options. He said the asset’s demand funnel had expanded as artificial intelligence companies seek infrastructure with the power, cooling, structural, ventilation and vibration specifications needed by lab users. During the question-and-answer session, McGraner said NexPoint would generally target life sciences and advanced manufacturing at roughly one-third of the portfolio, with residential representing about 50%.

He said the company could receive a substantial amount of capital back if the Alewife campus refinancing process is completed, with the goal of redeploying most of the proceeds into residential assets. McGraner also said the company’s self-storage portfolio continued to outperform, with occupancy in the low 90% range and rent growth and net operating income ahead of the broader sector. About NexPoint Real Estate Finance NREF NexPoint Real Estate Finance, Inc is a publicly traded real estate investment trust (REIT) focused on originating, acquiring and managing a diversified portfolio of commercial real estate debt investments.

The company seeks to generate current income and capital appreciation by providing financing solutions across the capital structure for stabilized and transitional properties. Its investments include whole loans, mezzanine loans, preferred equity and other structured credit products secured by multifamily, office, industrial, retail and hospitality assets. Since its initial public offering in March 2021, NexPoint Real Estate Finance has closed numerous transactions with borrowers nationwide, including both institutional sponsors and privately held owners.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. com. Where Should You Invest $1,000 Right Now? Before you make your next trade, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on...

and none of the big name stocks were on the list.